Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Arthritis & Rheumatology(2022)10.1002/art.42388Source: DataRank Database

Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis is a research paper published in Arthritis & Rheumatology (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.86)OA: hybridTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Sophie Hillion ORCID,Maximilian F. Konig ORCID,Marta Casal Moura ORCID,Amber M. Hummel,Eva M. Carmona ORCID

Live enrichment

PubMed:36281741 OpenAlex:https://openalex.org/W4307229229

National Institute of Allergy and Infectious Diseases

Grant: N01‐AI‐15416

National Institute of Allergy and Infectious Diseases

Grant: UM1‐AI‐109565

Foundation for the National Institutes of Health

Grant: UM1AI109565

National Institutes of Health

Grant: 3UM1AI109565-09S1

Immune Tolerance Network

National Institutes of Health

Grant: 1RC1AR058303-01

IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR VASCULITIS

National Institutes of Health

Grant: N01AI015416-003

IMMUNE TOLERANCE NETWORK-266015416

FWCI

2.86

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://doi.org/10.1002/art.42388

publisherhttps://doi.org/10.1002/art.42388

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42388

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/art.42388

publisherhttps://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/art.42388

Fields of Study

Vasculitis and related conditionsSystemic Sclerosis and Related DiseasesOtitis Media and Relapsing Polychondritis03 medical and health sciences0302 clinical medicine

MeSH Terms

RituximabHumansLeukocytes, MononuclearProspective StudiesRecurrenceAntibodies, Antineutrophil CytoplasmicMyeloblastinAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Keywords

RituximabB cellMedicineVasculitisImmunologyPeripheral blood mononuclear cellMemory B cellFlow cytometryAntibodyImmunophenotypingAnti-neutrophil cytoplasmic antibodyRegulatory B cellsProteinase 3Internal medicineGastroenterologyAutoantibodyBiologyIn vitroMyeloblastin610600Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisArticleAntibodies, Antineutrophil Cytoplasmicenvironment/HealthRecurrence[SDV.EE.SANT]Life Sciences [q-bio]/EcologyLeukocytes, MononuclearHumansProspective Studies

Sustainable Development Goals

SDG 0: Good health and well-being